<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982238</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190530-12</org_study_id>
    <nct_id>NCT03982238</nct_id>
  </id_info>
  <brief_title>Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients</brief_title>
  <official_title>Effects of Continuous Subcutaneous Insulin Infusion and Oral Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Majianhua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the total testosterone and sex hormone-binding globulin levels in men
      with type 2 diabetes before and after continuous subcutaneous insulin infusion and
      hypoglycemic drugs treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total testosterone levels</measure>
    <time_frame>1 month</time_frame>
    <description>changes of total testosterone levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bioavailable testosterone</measure>
    <time_frame>1 month</time_frame>
    <description>changes of bioavailable testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free testosterone</measure>
    <time_frame>1 month</time_frame>
    <description>changes of free testosterone</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continuous subcutaneous insulin infusion therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Continuous subcutaneous insulin infusion therapy for 1 month</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  volunteer to participate and be able to sign informed consent prior to the trial.

          -  patients with type 2 diabetes, aged 18-60 years old, meeting WHO1999 diagnostic
             criteria, have not used any hypoglycemic drugs.

          -  HbA1c &gt; 9%.

          -  subjects are able and willing to eat and exercise regularly.

        Exclusion Criteria:

          -  patients with insulin allergy.

          -  impaired liver and kidney function with ALT 2.5 times higher than the upper limit of
             normal value;Serum creatinine was 1.3 times higher than the upper limit of normal.‚óè
             drug abuse and alcohol dependence in the past 5 years.

          -  systemic hormone therapy was used in the last three months.

          -  patients with poor compliance and irregular diet and exercise.

          -  patients with infection and stress within 4 weeks.

          -  any other obvious conditions or associated diseases determined by the researcher: such
             as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors
             and other diseases, other pancreatic diseases, history of mental diseases.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Majianhua</investigator_full_name>
    <investigator_title>Director, Head of Endocrinology department, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

